Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
BCCIP product was isolated on the basis of its interaction with BRCA2 and p21 proteins. Additionally we are shipping BCCIP Proteins (9) and BCCIP Kits (3) and many more products for this protein.
Showing 10 out of 48 products:
Human Monoclonal BCCIP Primary Antibody for IF, WB - ABIN968821
Liu, Yuan, Huan, Shen: Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2. in Oncogene 2001
Show all 2 Pubmed References
this study identifies BCCIP as a novel factor critical for microtubule regulation and explicates a mechanism utilized by BCCIP in tumor suppression.
Expression of BCCIP beta was notably higher in tumor tissues of esophageal squamous cell carcinoma (ESCC) and Eca 109 cells. In vitro studies such as starvation and refeeding assay along with BCCIP beta-shRNA transfection assay demonstrated that BCCIP beta expression promoted proliferation of ESCC cells.
we demonstrate that BCCIPbeta induces a conformational change within the RAD51 (show RAD51 Antibodies) filament that promotes release of ADP to help maintain an active presynaptic filament. Our findings reveal a functional role for BCCIPbeta as a RAD51 (show RAD51 Antibodies) accessory factor in HR.
the existence of both INO80 (show INO80 Antibodies) and YY1 (show YY1 Antibodies) is required for recruiting the INO80 (show INO80 Antibodies)/YY1 (show YY1 Antibodies) complex to BCCIP promoter region. Our findings strongly indicate that BCCIP is a potential target gene of the INO80 (show INO80 Antibodies)/YY1 (show YY1 Antibodies) complex.
The BCCIPbeta, but not BCCIPalpha, interacts with EIF6 (show EIF6 Antibodies) and RPL23 (show RPL17 Antibodies)/UL14 and stabilizes the latter.
Results indicate that BCCIP germ line mutations are unlikely to be a major contributor to familial breast/ovarian cancer risk in our population.
In BRCA2 (show BRCA2 Antibodies), two novel frame shift mutations were identified as 5073-5074delCT and 6866delC.
BRCA2 (show BRCA2 Antibodies) germline mutations appear to have a milder clinical phenotype when compared to non-BRCA2 (show BRCA2 Antibodies) mutations, since survival is higher among breast cancer patients carrying a BRCA2 (show BRCA2 Antibodies) mutation compared to sporadic breast cancers.
Unique de novo mutation of BRCA2 (show BRCA2 Antibodies) has been identified in a woman with early onset breast cancer.
Overexpression of BCCIP beta delays the G1 to S progression and results in an elevated p21 (show CDKN1A Antibodies) expression
BCCIP represents a paradoxical class of modulators for tumorigenesis as a suppressor for initiation but a requisite for progression.
BCCIP and its anti-replication stress functions are essential for normal neural development by maintaining an orderly proliferation of neural progenitors.
these data suggest a unique function of BCCIP, not only in repair of DNA damage, but also in resolving stalled replication forks and prevention of replication stress
This gene product was isolated on the basis of its interaction with BRCA2 and p21 proteins. It is an evolutionarily conserved nuclear protein with multiple interacting domains. The N-terminal half shares moderate homology with regions of calmodulin and M-calpain, suggesting that it may also bind calcium. Functional studies indicate that this protein may be an important cofactor for BRCA2 in tumor suppression, and a modulator of CDK2 kinase activity via p21. This protein has also been implicated in the regulation of BRCA2 and RAD51 nuclear focus formation, double-strand break-induced homologous recombination, and cell cycle progression. Multiple transcript variants encoding different isoforms have been described for this gene.
BRCA2 and CDKN1A interacting protein
, protein BCCIP homolog
, BRCA2 and CDKN1A-interacting protein
, BRCA2 and Cip1/p21 interacting protein
, cdk inhibitor p21 binding protein
, p21- and CDK-associated protein 1
, protein TOK-1